title: A 2-way miRror of red blood cells and leukemia.
abstract: In this issue of Blood, the articles by Shaham et al and Wang et al are the first to identify microRNA 486 (miR-486) as a requisite oncomiR and credible therapeutic target in myeloid leukemia of Down syndrome (ML-DS) and chronic myeloid leukemia (CML) by showing that these 2 leukemias co-opt miR-486 functions in normal erythroid progenitor progrowth and survival activity.
authors.affiliation: CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER.
authors.forename: H Leighton
authors.initials: HL
authors.lastname: Grimes
authors.affiliation: CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER.
authors.forename: Sara E
authors.identifier: http://orcid.org/0000-0003-2930-748X
authors.initials: SE
authors.lastname: Meyer
mesh_terms: D000818:Animals; D049109:Cell Proliferation / Q000235:genetics*; D004314:Down Syndrome / Q000235:genetics*; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D004920:Erythropoiesis / Q000235:genetics*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics*; D015470:Leukemia, Myeloid, Acute / Q000235:genetics*; D055015:Megakaryocyte-Erythroid Progenitor Cells / Q000502:physiology*; D035683:MicroRNAs / Q000502:physiology*
chemical_list: C560945:MIRN486 microRNA, human; D035683:MicroRNAs